Frequent Links

Pathogenesis Scholarly journal supply-chain-management-open-access Best psychology journals Political Economy Cell Replacement Therapy for Diabetes Scholarly journal Alzheimer`s Disease Etiology Autism membrane protein peer review journals Evolution of Primatology Thoracic surgery Peer-review Journals Biodiesel process development Cardiology Scholarly Peer-review Journal Cell therapy impact factor Peer-review journals in autophagy Global warming-Open-Access-Journals

Open Access Articles- Top Results for 3F8

3F8

3F8^?
Monoclonal antibody
Source	Mouse
Target	GD2
Clinical data
Routes of administration	intravenous
Identifiers
CAS Registry Number	339169-93-6^7pxN
ATC code	None
Chemical data
14pxN (what is this?) (verify)

3F8 is a murine IgG3^[1] monoclonal antibody which binds to GD2.^[2]

It has been used in the detection and treatment of neuroblastoma.^[3] For imaging neuroblastoma, it is labelled with one of the radioisotopes iodine-124 and iodine-131.^[4]^[5]

References

↑ Kushner BH, Cheung NK (1989). "GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma". Blood 73 (7): 1936–41. PMID 2653466.
↑ "Sloan-Kettering - Neuroblastoma: 3F8 Monoclonal Antibody Therapy Q & A". Retrieved 2008-02-19.
↑ Weinstein, J. L. (1 June 2003). "Advances in the Diagnosis and Treatment of Neuroblastoma". The Oncologist 8 (3): 278–292. doi:10.1634/theoncologist.8-3-278.
↑ Yeh SD, Larson SM, Burch L et al. (1991). "Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities". J. Nucl. Med. 32 (5): 769–76. PMID 1902508.
↑ Dauer LT, St Germain J, Williamson MJ et al. (2007). "Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma". Health Phys 92 (1): 33–9. PMID 17164597. doi:10.1097/01.HP.0000231583.32904.6c.

Monoclonal antibodies for tumors

Tumor
("-t(u[m])-")

Human ("-tumu-")	Adecatumumab Cixutumumab Conatumumab Daratumumab Drozitumab Duligotumab Dusigitumab Enfortumab vedotin Figitumumab Ganitumab Glembatumumab vedotin Intetumumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Narnatumab Necitumumab Ofatumumab Olaratumab Panitumumab Patritumab Pritumumab Radretumab Rilotumumab Robatumumab Seribantumab Teprotumumab Tovetumab Vantictumab Votumumab Zalutumumab "-melu-" (melanoma) Flanvotumab

Mouse ("-tumo-")	Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab CC49 Detumomab Ibritumomab tiuxetan Minretumomab Mitumomab Moxetumomab pasudotox Naptumomab estafenatox Nofetumomab merpentan Pemtumomab^† Pintumomab Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Tenatumomab Tositumomab 3F8 "-govo-" (ovarian tumor) Abagovomab Igovomab Oregovomab "-pro-" (prostate tumor) Capromab pendetide "-colo-" (colonic tumor) Edrecolomab Nacolomab tafenatox

Chimeric ("-tuxi-")	Amatuximab Bavituximab Brentuximab vedotin Cetuximab Derlotuximab biotin Dinutuximab Ensituximab Futuximab Girentuximab Indatuximab ravtansine Isatuximab Margetuximab Rituximab Siltuximab Ublituximab "-mexi-" (melanoma): Ecromeximab

Humanized ("-tuzu-")	Alemtuzumab Bevacizumab Bivatuzumab mertansine Cantuzumab mertansine Cantuzumab ravtansine Citatuzumab bogatox Clivatuzumab tetraxetan Dacetuzumab Dalotuzumab Elotuzumab^† Emibetuzumab Enoblituzumab Etaracizumab Farletuzumab Ficlatuzumab Gemtuzumab ozogamicin Imgatuzumab Inotuzumab ozogamicin Labetuzumab Lifastuzumab vedotin Lintuzumab Lorvotuzumab mertansine Matuzumab^§ Milatuzumab Nimotuzumab Obinutuzumab Ocaratuzumab Otlertuzumab Onartuzumab Oportuzumab monatox Parsatuzumab Pertuzumab Pinatuzumab vedotin Polatuzumab vedotin Sibrotuzumab Simtuzumab Tacatuzumab tetraxetan Tigatuzumab Trastuzumab Tucotuzumab celmoleukin Veltuzumab Vorsetuzumab mafodotin "-gozu-" (ovarian tumor) Sofituzumab vedotin

Rat/mouse hybrid ("-tumaxo-")	Catumaxomab Ertumaxomab

Chimeric + humanized ("-tuxizu-")	Ontuxizumab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

v t e Index of neoplasms and cancer

Description	Tumor suppressing and oncogenes Tumor markers Carcinogen

Disease	Neoplasms and cancer Symptoms and signs Paraneoplastic

Treatment	Radiotherapy Drugs Immunotherapy intracellular chemotherapeutics extracellular chemotherapeutics adjuvant detoxification

Lua error in package.lua at line 80: module 'Module:Buffer' not found. Lua error in package.lua at line 80: module 'Module:Buffer' not found.

Search

Actions

Journals

Adverts

Frequent Links

Open Access Articles- Top Results for 3F8

3F8

See also

References